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GRAFf-versus-host disease (GVHD) has always been a 
concern associated with small bowel transplantation, 
because of the large amount of matured lymphocytes 
contained in the graft. In clinical organ transplantation 
GVHD is not a common complication; however, it is usually 
fatal once developed. Because there is no suitable experi-
mental model of GVHD associated with solid organ trans-
plantation, studies investigating the pathogenesis and treat-
ment of this disease have been limited. We describe here a 
clinically relevant animal model of GVHD after fully 
allogeneic small bowel transplantation. 
MATERIALS AND METHODS 
Inbred Lewis (RTl') and ACI (RTla) rats (Harlan Sprague Daw-
ley, Indianapolis. Ind.) were used as recipients and donors. respec-
tively. Orthotopic small bowel transplantation (SBTX), bone mar-
row cell (250 X 106) infusion (BMTX), and simultaneous SBTX 
with BMTX were performed according to the procedures previ-
ously described. 1 FK 506 was intramuscularly administered at a 
daily dose of 1 mglkg on days 0 to 13, then continued as a weekly 
injection at the same dose for 400 days. GVHD was clinically 
defined as skin rash, hyperkeratosis. and body weight loss. followed 
by histopathologic examination. The number of donor cells in the 
recipient circulation was determined by flow cytometry using 
monoclonal antibodies specific for donor and recipient class I 
MHC (MN4.91-6 and 163). 
RESULTS 
Under continuous FK 506 immunosuppression. graft sur-
vival was prolonged with median survivals of 270. > 232. and 
229 days after SBTX (n = 4). BMTX (n = 5). and SBTX + 
BMTX (n = 7), respectively. Clinical signs of GVHD were 
seen in 25% (SBTX), 80% (BMTX), and 100% (SBTX + 
BMTX) of these recipients with median onset time of 180. 
131.5. and 89 days, respectively. Histopathologic examina-
tion of skin in these animals confirmed GVHD. Eventual 
animal death was not affected by rejection and caused by 
GVHD, infection. or surgery-related complication, such as 
volvulus. In SBTX recipients the number of donor cells 
reached 5% to 10% during the first week after transplan-
tation. Donor cells declined with time and were no longer 
detected by flow cytometry 50 days after transplantation. 
After BMTX few. but clearly stained, donor cells (0.2% to 
1.5%) persisted in the recipient blood for >200 days. 
However. the development of GVHD in these BMTX 
animals was not associated with the increase of donor cells. 
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When the small bowel and bone marrow were transplanted 
together, donor cells were easily found and accounted for 
3% to 7.3% during the first 2 weeks after transplantation. 
The number gradually increased with time and the evolu-
tion of donor cells was generally associated with the devel-
opment of skin rash and hyperkelatosis. These signs of 
GVHD waxed and waned under continuous FK S06 treat-
ment, and donor cells inflected between 5% and 20% of the 
circulating lymphocytes. 
DISCUSSION 
These results demonstrate that simultaneous small bowel 
and bone marrow cell transplantation significantly en-
hanced the engraftment of donor cells. However, this 
procedure also risks the development of GVHD, which 
persisted and became a chronic form for the rest of the 
experimental period under continuous low-dose immuno-
suppression. Since Monchik and Russel demonstrated that 
the small bowel graft was able to induce GVHD in Fl 
hybrid recipients, this unidirectional transplantation model 
has been widely used for studying GVHD.2 Our current 
understanding of the two-way paradigm in organ transplan-
tation is based on the reciprocal host-graft immune reac-
tions.3 The experimental model described here will be a 
useful tool to further study the pathogenesis of the disease 
and develop strategies for prevention or treatment of 
GVHD based on the two-way interactions between the graft 
and host. 
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